Overview

N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE

Status:
Not yet recruiting

Trial end date:
2022-09-07

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Caen

Treatments:

Acetylcysteine
N-monoacetylcystine